Trials / Completed
CompletedNCT00749632
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- FemmePharma Global Healthcare, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oxybutynin | low dose oxybutynin administered daily |
| DRUG | oxybutynin | middle dose oxybutynin administered daily |
| DRUG | oxybutynin | high dose oxybutynin administered daily |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-09-09
- Last updated
- 2009-10-15
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00749632. Inclusion in this directory is not an endorsement.